CN111032688A - 用于延长的血清半衰期的工程化抗体fc变体 - Google Patents

用于延长的血清半衰期的工程化抗体fc变体 Download PDF

Info

Publication number
CN111032688A
CN111032688A CN201880051999.9A CN201880051999A CN111032688A CN 111032688 A CN111032688 A CN 111032688A CN 201880051999 A CN201880051999 A CN 201880051999A CN 111032688 A CN111032688 A CN 111032688A
Authority
CN
China
Prior art keywords
polypeptide
domain
antibody
binding
fcrn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880051999.9A
Other languages
English (en)
Chinese (zh)
Inventor
乔治·乔治乌
李昌翰
姜泰贤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Development Foundation
Original Assignee
Research Development Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Development Foundation filed Critical Research Development Foundation
Publication of CN111032688A publication Critical patent/CN111032688A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN201880051999.9A 2017-08-11 2018-08-11 用于延长的血清半衰期的工程化抗体fc变体 Pending CN111032688A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762544622P 2017-08-11 2017-08-11
US62/544,622 2017-08-11
PCT/US2018/046398 WO2019033087A1 (en) 2017-08-11 2018-08-11 MODIFIED FC ANTIBODY VARIANTS FOR ENHANCED SERIAL HALF LIFE

Publications (1)

Publication Number Publication Date
CN111032688A true CN111032688A (zh) 2020-04-17

Family

ID=65272701

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880051999.9A Pending CN111032688A (zh) 2017-08-11 2018-08-11 用于延长的血清半衰期的工程化抗体fc变体

Country Status (9)

Country Link
US (3) US11059892B2 (enExample)
EP (1) EP3665195A4 (enExample)
JP (3) JP7191087B2 (enExample)
KR (1) KR102867311B1 (enExample)
CN (1) CN111032688A (enExample)
AU (1) AU2018314257B2 (enExample)
CA (1) CA3072099A1 (enExample)
IL (1) IL272561A (enExample)
WO (1) WO2019033087A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7762645B2 (ja) * 2019-08-22 2025-10-30 シダラ セラピューティクス インコーポレーテッド バリアントｆｃドメイン及びその使用
BR112022019131A2 (pt) * 2020-05-21 2022-11-29 Zydus Lifesciences Ltd Variante fc e composiçâo
WO2022103758A1 (en) * 2020-11-11 2022-05-19 Gilead Sciences, Inc. METHODS OF IDENTIFYING HIV PATIENTS SENSITIVE TO THERAPY WITH gp120 CD4 BINDING SITE-DIRECTED ANTIBODIES
WO2022169825A1 (en) 2021-02-03 2022-08-11 Mozart Therapeutics, Inc. Binding agents and methods of using the same
AU2022253902A1 (en) 2021-04-10 2023-11-02 Genmab A/S Folr1 binding agents, conjugates thereof and methods of using the same
TW202308699A (zh) 2021-04-23 2023-03-01 美商普方生物製藥美國公司 Ｃｄ７０結合劑、其結合物及其使用方法
TW202320857A (zh) 2021-07-06 2023-06-01 美商普方生物製藥美國公司 連接子、藥物連接子及其結合物及其使用方法
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
WO2023108115A1 (en) * 2021-12-10 2023-06-15 Board Of Regents, The University Of Texas System Ph-selective antibody fc domains
WO2024030956A2 (en) 2022-08-03 2024-02-08 Mozart Therapeutics, Inc. Cd39-specific binding agents and methods of using the same
AU2023330037A1 (en) 2022-08-26 2025-03-06 Gilead Sciences, Inc. Dosing and scheduling regimen for broadly neutralizing antibodies
WO2024243423A1 (en) 2023-05-24 2024-11-28 Mozart Therapeutics, Inc. Cd8-specific binding proteins and methods of using the same
WO2025014773A1 (en) 2023-07-07 2025-01-16 Viridian Therapeutics, Inc. Methods of treating chronic thyroid eye disease
AR133955A1 (es) 2023-09-26 2025-11-19 Profoundbio Us Co Agentes de unión a ptk7, conjugados de éstos y métodos de uso de los mismos
TW202535955A (zh) 2023-11-27 2025-09-16 丹麥商珍美寶股份有限公司 用於ｐｔｋ７檢測之抗體及方法
US20250296992A1 (en) 2024-01-10 2025-09-25 Genmab A/S Slitrk6 binding agents, conjugates thereof and methods of using the same
WO2025171006A1 (en) * 2024-02-06 2025-08-14 Paragon Therapeutics, Inc. Il-23 binding protein compositions and methods of use
WO2025181219A1 (en) 2024-02-29 2025-09-04 Genmab A/S Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same
WO2025222129A2 (en) 2024-04-19 2025-10-23 Mozart Therapeutics, Inc. Engineered cytokines and targeted cytokine delivery

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120128663A1 (en) * 2004-11-12 2012-05-24 Xencor, Inc. Fc VARIANTS THAT EXTEND ANTIBODY HALF-LIFE
US20130209457A1 (en) * 2003-05-02 2013-08-15 Xencor, Inc. Optimized Fc Variants
CN103748110A (zh) * 2011-07-19 2014-04-23 葛兰素集团有限公司 具有增加的FcRn结合的抗原结合蛋白
CN103958547A (zh) * 2011-09-30 2014-07-30 中外制药株式会社 具有促进抗原清除的FcRn结合结构域的治疗性抗原结合分子
CN106413750A (zh) * 2014-05-16 2017-02-15 免疫医疗有限责任公司 具有增强的治疗和诊断特性的带有改变的新生儿Fc受体结合的分子

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7094571B2 (en) 2000-10-27 2006-08-22 The Board Of Regents Of The University Of Texas System Combinatorial protein library screening by periplasmic expression
US7419783B2 (en) 2001-11-05 2008-09-02 Research Development Foundation Engineering of leader peptides for the secretion of recombinant proteins in bacteria
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
DE60310385T2 (de) 2002-03-23 2007-09-20 Research Development Foundation, Carson City Sekretion von proteinen mit mehreren disulfidbindungen in bakterien und verwendungen davon
US7611866B2 (en) 2002-07-15 2009-11-03 Board Of Regents, The University Of Texas System Selection of bacterial inner-membrane anchor polypeptides
AU2004290070A1 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Neonatal Fc receptor (FcRn)-binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
US7632497B2 (en) 2004-11-10 2009-12-15 Macrogenics, Inc. Engineering Fc Antibody regions to confer effector function
CN102746404B (zh) 2004-11-12 2016-01-20 赞科股份有限公司 对FcRn的结合被改变的Fc变体
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
EP1858925A2 (en) 2005-01-12 2007-11-28 Xencor, Inc. Antibodies and fc fusion proteins with altered immunogenicity
CA2716990A1 (en) 2007-03-07 2008-09-12 Aarhus Universitet Pig model for atherosclerosis
US8629245B2 (en) 2007-05-01 2014-01-14 Research Development Foundation Immunoglobulin Fc libraries
JP5683581B2 (ja) 2009-06-30 2015-03-11 リサーチ ディベロップメント ファウンデーション 免疫グロブリンＦｃポリペプチド
TWI667346B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的FcRn親和力之抗體
WO2013047748A1 (ja) 2011-09-30 2013-04-04 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
CN104010659A (zh) * 2011-12-19 2014-08-27 洛克菲勒大学 非唾液酸化的抗炎多肽
DK2857419T3 (da) 2012-05-30 2021-03-29 Chugai Pharmaceutical Co Ltd Antigen-bindende molekyle til eliminering af aggregerede antigener
JP6034332B2 (ja) * 2014-05-30 2016-11-30 トヨタ自動車株式会社 組換え微生物及び当該組換え微生物を用いた物質製造方法
HUE045466T2 (hu) * 2014-11-06 2019-12-30 Hoffmann La Roche Fc-régió-variánsok módosított FcRn-kötéssel és alkalmazási eljárások
PL3661954T3 (pl) 2017-08-03 2022-05-16 Amgen Inc. Muteiny interleukiny 21 i sposoby leczenia

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130209457A1 (en) * 2003-05-02 2013-08-15 Xencor, Inc. Optimized Fc Variants
US20120128663A1 (en) * 2004-11-12 2012-05-24 Xencor, Inc. Fc VARIANTS THAT EXTEND ANTIBODY HALF-LIFE
CN103748110A (zh) * 2011-07-19 2014-04-23 葛兰素集团有限公司 具有增加的FcRn结合的抗原结合蛋白
CN103958547A (zh) * 2011-09-30 2014-07-30 中外制药株式会社 具有促进抗原清除的FcRn结合结构域的治疗性抗原结合分子
CN106413750A (zh) * 2014-05-16 2017-02-15 免疫医疗有限责任公司 具有增强的治疗和诊断特性的带有改变的新生儿Fc受体结合的分子

Also Published As

Publication number Publication date
JP2025013474A (ja) 2025-01-24
IL272561A (en) 2020-03-31
AU2018314257A1 (en) 2020-02-13
KR20200035972A (ko) 2020-04-06
KR102867311B1 (ko) 2025-10-01
CA3072099A1 (en) 2019-02-14
EP3665195A4 (en) 2021-05-19
US11059892B2 (en) 2021-07-13
AU2018314257B2 (en) 2025-03-27
JP2020530296A (ja) 2020-10-22
US11958904B2 (en) 2024-04-16
US20240270852A1 (en) 2024-08-15
JP7583767B2 (ja) 2024-11-14
US20210347891A1 (en) 2021-11-11
JP7191087B2 (ja) 2022-12-16
JP2022145845A (ja) 2022-10-04
WO2019033087A1 (en) 2019-02-14
EP3665195A1 (en) 2020-06-17
US20190048078A1 (en) 2019-02-14

Similar Documents

Publication Publication Date Title
CN111032688A (zh) 用于延长的血清半衰期的工程化抗体fc变体
US10689449B2 (en) Multimeric death domain-containing receptor-5 (DR5) antibodies and uses thereof
EP3575323B1 (en) Anti-dr5 family antibodies, bispecific or multivalent anti-dr5 family antibodies and methods of use thereof
WO2023020621A1 (en) Anti-ccr8 antibodies and uses thereof
KR20210074279A (ko) 항-her2 폴리펩타이드 및 이의 사용방법
AU2020281378B2 (en) Anti-TrkA antibodies and uses thereof
JP2022513653A (ja) 修飾された重鎖定常領域を含む抗体
JP2023544143A (ja) 抗クローディン１８．２および抗ｃｄ３二重特異性抗体およびその使用
AU2021234327A1 (en) Materials and methods for modulating delta chain mediated immunity
CN115175694A (zh) 抗baff受体抗体及其用途
CA3213285A1 (en) Bioengineered immunomodulatory fusion protein compositions
CN115279412A (zh) 偶联脂肪酸分子的抗体及其用途
JP2024505673A (ja) 電荷対を有する二重特異性抗体及びその使用
US20250188186A1 (en) Ph-selective antibody fc domains
US20250270346A1 (en) Efficacious anti-cd26 antibody biomarker
JP2024536133A (ja) 抗ｈｓｐ７０抗体およびその治療的使用
CN107614524A (zh) 治疗
TWI880048B (zh) 人源化抗ＴｒｋＡ的抗體及其應用
CN120530135A (zh) 抗b7h3抗体和使用方法
CN120603850A (zh) 抗cmet抗体及使用方法
CN119816519A (zh) 抗ror1抗体、包含其的双特异性抗体及其用途
TW202539735A (zh) 一種包含特異性結合ｄｌｌ３和ｃｄ３的雙特異性抗體的醫藥組成物
CN120437287A (zh) 一种包含特异性结合gucy2c和cd3的双特异性抗体的药物组合物
HK40043005A (en) Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof
HK40082596A (en) Antibodies conjugated with fatty acid molecules and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination